
    
      This study consists of 2 periods and 2 parts. Participants will be placed in Part 1 or Part
      2, and cannot participate in both:

      Part 1, Period 1 includes a screening period up to 28 days prior to dosing and treatment on
      Day 1.

      Part 1, Period 2 includes a treatment period from Day 1 to Day 9 and a possible follow-up, up
      to 28 days after the last dose of study drug.

      Part 2, Period 1 includes a screening period up to 28 days prior to dosing and treatment on
      Day 1.

      Part 2, Period 2 includes a treatment period from Day 1 to Day 12 and a possible follow-up,
      up to 28 days after the last dose of study drug.
    
  